Hepatitis C Infection Is Not a Cardiovascular Risk Factor in Young Adults

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457712

Authors

Pawel Rajewski

Malgorzata Pawlowska

Dorota Kozielewicz

Dorota Dybowska

Anita Olczak

Jakub Ciescinski

Affiliations

Soon will be listed here.

Abstract

: Cardiovascular diseases are one of the leading causes of hospitalization and death in Poland and around the world and are still an ongoing problem for modern medicine. Despite advances in diagnosis and treatment, both conservative and invasive, the prevention of cardiovascular disease directed at reducing risk factors remains a problem. The main classical risk factors for the development of cardiovascular disease in Poland include hypertension, lipid disorders, obesity, diabetes and smoking. A new non-classical risk factor is HCV infection. Most of the studies on the impact of HCV infection on cardiovascular disease involve elderly populations with long-term infections and advanced liver fibrosis. : Hence, we set out to analyze the prevalence of risk factors and cardiovascular disease in a population of young adults under 45 years of age infected with HCV, according to gender, HCV genotype and the duration of infection. The study group consisted of 217 patients of both sexes aged 21 to 45 years (mean age 36 years). : No cardiovascular disease was found among the young adults infected with HCV in the study group. The most common risk factor was cigarette smoking, which affected 20.7% of the subjects, followed by hypertension (12%) and diabetes mellitus (5.5%); the prevalence was lower than in the general population. Most of the patients were characterized as overweight, with a mean BMI of 26.39 kg/m. The mean values of other metabolic parameters-total cholesterol, LDL, HDL, uric acid and glucose-were within the population norm. The mean value of CRP was 1.43, which may indicate a moderate cardiovascular risk. : Based on the conducted research, it was found that HCV infection in young individuals was not a risk factor for cardiovascular diseases, and the prevalence of risk factors was similar to that in the general population. The effect of HCV on the increase in C-reactive protein requires further study. The early detection of HCV infection and treatment can be considered as a prevention of cardiovascular disease.

References

Feig D, Kang D, Johnson R . Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17):1811-21. PMC: 2684330. DOI: 10.1056/NEJMra0800885. View

Negro F, Alberti A . The global health burden of hepatitis C virus infection. Liver Int. 2011; 31 Suppl 2:1-3. DOI: 10.1111/j.1478-3231.2011.02537.x. View

Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F . Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012; 12 Suppl 2:S2. PMC: 3495628. DOI: 10.1186/1471-2334-12-S2-S2. View

Amezcua-Castillo E, Gonzalez-Pacheco H, Saenz-San Martin A, Mendez-Ocampo P, Gutierrez-Moctezuma I, Masso F . C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine. Biomedicines. 2023; 11(9). PMC: 10525787. DOI: 10.3390/biomedicines11092444. View

Liberale L, Badimon L, Montecucco F, Luscher T, Libby P, Camici G . Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022; 79(8):837-847. PMC: 8881676. DOI: 10.1016/j.jacc.2021.12.017. View

Wu A, Lindson N, Hartmann-Boyce J, Wahedi A, Hajizadeh A, Theodoulou A . Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022; 8:CD014936. PMC: 9358996. DOI: 10.1002/14651858.CD014936.pub2. View

Roubille F, Cherbi M, Kalmanovich E, Delbaere Q, Bonnefoy-Cudraz E, Puymirat E . The admission level of CRP during cardiogenic shock is a strong independent risk marker of mortality. Sci Rep. 2024; 14(1):16338. PMC: 11252392. DOI: 10.1038/s41598-024-67556-y. View

Iwakiri Y, Groszmann R . The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43(2 Suppl 1):S121-31. DOI: 10.1002/hep.20993. View

Rajewski P, Zarebska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M . Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study. J Clin Med. 2022; 11(17). PMC: 9456581. DOI: 10.3390/jcm11175193. View

10.

Lecube A, Hernandez C, Genesca J, Simo R . Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care. 2006; 29(5):1096-101. DOI: 10.2337/diacare.2951096. View

11.

Chang C, Wu C, Liu L, Chou R, Kuo C, Huang P . Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. Sci Rep. 2018; 8(1):5234. PMC: 5869680. DOI: 10.1038/s41598-018-22997-0. View

12.

Keto J, Ventola H, Jokelainen J, Linden K, Keinanen-Kiukaanniemi S, Timonen M . Cardiovascular disease risk factors in relation to smoking behaviour and history: a population-based cohort study. Open Heart. 2016; 3(2):e000358. PMC: 4947752. DOI: 10.1136/openhrt-2015-000358. View

13.

Mora-Ramirez M, Estevez-Garcia I, Irigoyen-Camacho M, Bojalil R, Gonzalez-Pacheco H, Amezcua-Guerra L . Hyperuricemia on Admission Predicts Short-Term Mortality due to Myocardial Infarction in a Population with High Prevalence of Cardiovascular Risk Factors. Rev Invest Clin. 2017; 69(5):247-253. DOI: 10.24875/ric.17002167. View

14.

. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022; 7(5):396-415. DOI: 10.1016/S2468-1253(21)00472-6. View

15.

Moller S, Henriksen J . Cardiovascular complications of cirrhosis. Gut. 2008; 57(2):268-78. DOI: 10.1136/gut.2006.112177. View

16.

Klover P, Zimmers T, Koniaris L, Mooney R . Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003; 52(11):2784-9. DOI: 10.2337/diabetes.52.11.2784. View

17.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

18.

Petta S, Maida M, Macaluso F, Barbara M, Licata A, Craxi A . Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2015; 150(1):145-155.e4. DOI: 10.1053/j.gastro.2015.09.007. View

19.

Petta S, Adinolfi L, Fracanzani A, Rini F, Caldarella R, Calvaruso V . Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018; 69(1):18-24. DOI: 10.1016/j.jhep.2018.02.015. View

20.

Zdrojewski T, Jankowski P, Bandosz P, Bartus S, Chwojnicki K, Drygas W . [A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population]. Kardiol Pol. 2015; 73(10):958-61. DOI: 10.5603/KP.2015.0182. View